{"id":1820,"date":"2018-06-06T17:40:25","date_gmt":"2018-06-06T21:40:25","guid":{"rendered":"https:\/\/cqdm.org\/en\/news-and-events\/cqdm-to-support-a-1-1-m-rd-project-for-immune-biosolutions-next-generation-of-anti-cancer-treatment\/"},"modified":"2024-09-25T16:28:05","modified_gmt":"2024-09-25T20:28:05","slug":"cqdm-to-support-a-1-1-m-rd-project-for-immune-biosolutions-next-generation-of-anti-cancer-treatment","status":"publish","type":"post","link":"https:\/\/cqdm.org\/en\/news-and-events\/cqdm-to-support-a-1-1-m-rd-project-for-immune-biosolutions-next-generation-of-anti-cancer-treatment\/","title":{"rendered":"CQDM to support a $1.1 M R&D project for Immune Biosolutions\u2019 next-generation of anti-cancer treatment"},"content":{"rendered":"\n

BOSTON, JUNE 6, 2018<\/strong> \u2013 CQDM is pleased to announce the funding of a new $1.1 million research project in conjunction with financial contributions from lead industrial partner, Immune Biosolutions, and co-funding from: Cancer Research Society, Mitacs, Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke and TransferTech. The funds will be used by the Universit\u00e9 de Sherbrooke\u2019s Professors Fernand Gobeil, Philippe Sarret and Fernand-Pierre Gendron and their respective teams to further develop Immune Biosolutions\u2019 lead therapeutic antibody candidates to fight cancer.<\/p>\n\n\n\n

CQDM is supporting this project through its SynergiQC program, focusing on industrial research through public and private funding, made possible by a financial contribution from the Ministry of Economy, Science and Innovation (MESI) of the Government of Quebec.<\/p>\n\n\n\n

\u00ab La mise en commun des expertises d\u00e9velopp\u00e9es par chacun des partenaires du CQDM concourra au succ\u00e8s de ce projet de recherche prometteur pour la lutte contre le cancer. L\u2019\u00e9tablissement de partenariats fructueux se trouve d\u2019ailleurs au c\u0153ur de la Strat\u00e9gie qu\u00e9b\u00e9coise des sciences de la vie, gr\u00e2ce \u00e0 laquelle le Qu\u00e9bec a le potentiel de se hisser parmi les cinq p\u00f4les nord-am\u00e9ricains les plus importants de ce secteur d\u2019ici 2027 \u00bb, souligne la vice-premi\u00e8re ministre, ministre de l\u2019\u00c9conomie, de la Science et de l\u2019Innovation et ministre responsable de la Strat\u00e9gie num\u00e9rique, madame Dominique Anglade.<\/em><\/p>\n\n\n\n

\u00ab Nous pouvons nous r\u00e9jouir d\u2019un tel partenariat, auquel participe notamment une installation de recherche du r\u00e9seau de la sant\u00e9 et des services sociaux, et des retomb\u00e9es positives qu\u2019aura ce projet sur la qualit\u00e9 et l\u2019efficacit\u00e9 des soins offerts aux usagers. Nous nous sommes engag\u00e9s collectivement \u00e0 faire de notre lutte contre le cancer une priorit\u00e9, et je suis persuad\u00e9 que c\u2019est par des initiatives collectives d\u2019une telle port\u00e9e que nous parviendrons le mieux \u00e0 mener ce combat, ensemble, au b\u00e9n\u00e9fice de toute la population qu\u00e9b\u00e9coise \u00bb, a d\u00e9clar\u00e9 le ministre de la Sant\u00e9 et des Services sociaux, monsieur Ga\u00e9tan Barrette.<\/em><\/p>\n\n\n\n

Funding will support the demonstration of the in vivo<\/em> efficacy and safety of novel therapeutic chicken antibodies generated by Immune Biosolutions\u2019 proprietary Nebula\u2122 Platform. This research will demonstrate the disruptive discovery capacity of this platform for potentially effective but still largely unexploited targets due to their complex structure and high conformational variability. The highly specific anti-cancer antibodies developed in this project will target two attractive G-protein-coupled receptors\u2014namely bradykinin receptor B1 (B1R) and neurotensin receptor 1 (NTSR1)\u2014for the treatment of solid cancers such as colorectal and non-small cell lung cancers (for NTSR1), as well as prostate and triple-negative breast cancers (for B1R). This project\u2019s overarching goal is to position these development programs toward clinical studies, providing a springboard for Immune Biosolutions to develop its own candidate humanized antibody pipeline against diseases with high medical unmet needs.<\/p>\n\n\n\n

“Professors Gobeil, Sarret and Gendron\u2019s expertise in GPCRs, drug development and cancer research at the Universit\u00e9 de Sherbrooke will be key for the validation and optimization of Immune Biosolutions\u2019 lead therapeutics antibodies. The potential of the Nebula Platform for generating therapeutics antibodies is huge, and its validation through this project could pave the way for humanized chicken antibodies to be deployed against many cancers and other diseases currently lacking effective treatments,” said Frederic Leduc, CEO of Immune Biosolutions.<\/p>\n\n\n\n

\u201cCQDM is very proud to fund this collaborative project between Immune Biosolutions (an early-stage biotechnology company based in Sherbrooke) and Universit\u00e9 de Sherbrooke to develop a game-changing technology to fight cancer. This project encompasses the main purpose of CQDM\u2019s SynergiQc program to fund industrial research within academic settings and allow Quebec-based companies to break new ground while benefiting from the expertise and infrastructure found in Quebec universities,\u201d said Diane Gosselin, CEO of CQDM.<\/p>\n\n\n\n

About CQDM
<\/strong>CQDM is a pharma-based consortium whose mission is to fund the development of innovative tools and technologies that accelerate drug discovery. A unique organization, CQDM\u2019s business model is based on a collaborative approach where all stakeholders share the costs of biopharmaceutical research, and benefit from its results. CQDM also provides a common meeting ground where academia, governments and the pharmaceutical and biotechnology industries converge to address numerous complex medical challenges. Industrial members of CQDM include Merck, Pfizer, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Eli Lilly Canada, Janssen, Novartis Pharma Canada, Sanofi Canada, Servier, Roche, Takeda, as well as from Quebec\u2019s Ministry of Economy, Science and Innovation (MESI) and from the Government of Canada under the Business-Led Networks of Centres of Excellence Program (BL-NCE). For more information: www.cqdm.org\/fr<\/a><\/p>\n\n\n\n

About Immune Biosolutions <\/strong>
Immune Biosolutions (IBio) is an innovative biotech company specialized in the discovery and engineering of chicken edible and humanized antibodies that target proteins with a recognized, yet unexploited, therapeutic potential. IBio\u2019s focus is to change the odds of antibody discovery against traditionally difficult targets, such as GPCRs and other membranes proteins. Through its Nebula Antibody Platform, Immune Biosolutions generates high-value recombinant antibody portfolios that can target, as well as modulate, membrane proteins. Immune Biosolutions\u2019 current pipeline of therapeutic programs includes three GPCR programs known to be overexpressed in several cancers, and for which IBio is currently validating their therapeutic potential. For more information: www.ibiosolutions.com<\/a><\/p>\n\n\n\n

About the Cancer Research Society
<\/strong>Founded in 1945, the Cancer Research Society is the first Canadian organization entirely devoted to funding research on all types of cancer. Over the course of its history, the CRS has supported thousands of our country’s best scientific minds who have helped make important strides in the way we prevent, detect, and treat cancer. Since 2000, thanks to the generosity of donors across the country, the CRS distributed over $140 million in research grants. For more information: www.CancerResearchSociety.ca<\/a><\/p>\n\n\n\n

About Mitacs
<\/strong>Mitacs is a national, not-for-profit organization that has designed and delivered research and training programs in Canada for 19 years. Working with 60 universities, thousands of companies and both federal and provincial governments, Mitacs builds partnerships that support industrial and social innovation in Canada. Open to all disciplines and all industry sectors, projects can span a wide range of areas, including manufacturing, business processes, IT, social sciences, design and more. For more information: www.mitacs.ca<\/a><\/p>\n\n\n\n

                                                                                                                                     – 30 –<\/p>\n\n\n\n

For additional information, please contact:
<\/strong>Marc Thibault
Director of Business Development
CQDM
Tel: 514 766 6661, ext. 2190<\/p>\n\n\n\n

Catherine W. Audet
Attach\u00e9e de presse
Cabinet du ministre de la Sant\u00e9 et des Services sociaux
T\u00e9l. : 418 266-7171<\/em><\/p>\n\n\n\n

Gabrielle Fallu
Attach\u00e9e de presse
Cabinet de la vice-premi\u00e8re ministre, ministre de l’\u00c9conomie, de la Science et de l’Innovation et ministre responsable de la Strat\u00e9gie num\u00e9rique>
T\u00e9l. : 418 691-5650<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

BOSTON, JUNE 6, 2018 \u2013 CQDM is pleased to announce the funding of a new $1.1 million research project in conjunction with financial contributions from lead industrial partner, Immune Biosolutions, and co-funding from: Cancer Research Society, Mitacs, Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke and TransferTech. The funds will be used by the Universit\u00e9…<\/p>\n","protected":false},"author":2,"featured_media":1022,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1820","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-our-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts\/1820","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/comments?post=1820"}],"version-history":[{"count":1,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts\/1820\/revisions"}],"predecessor-version":[{"id":4388,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts\/1820\/revisions\/4388"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media\/1022"}],"wp:attachment":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media?parent=1820"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/categories?post=1820"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/tags?post=1820"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}